• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

My two detailed comments on the Cochrane Exercise Therapy for CFS review (2015)

Tom Kindlon

Senior Member
Messages
1,734
Comment on: Exercise therapy for chronic fatigue syndrome. Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Cochrane Database Syst Rev. 2015 Feb 10;2:CD003200.

Author: Tom Kindlon

Comment 1 of 2 submitted on September 9, 2015

I would first like to thank those involved for their work in preparing this document. Even for those of us who have read the individual Chronic Fatigue Syndrome (CFS) papers it is useful to have the results collated, as well as details regarding the interventions. Also it is interesting to see the results of sensitivity analyses, subgroup analyses, standardised mean differences, etc.

I would like to make a few comments. I’m splitting them into two submissions as the piece had become very long. I’ve added some loose headings to hopefully make it more readable.

Objective measures

The review assessed the studies as having a high risk of bias regarding blinding, since neither participants nor assessors were blinded. Evidence suggests that subjective outcomes are more prone to bias than objective outcomes when there is no blinding (1). It is thus unfortunate that the review concentrated almost exclusively on subjective measures, failing to include results from nearly all the objective outcome measures that have been published with trials. (The exception was health resource use for which you presented follow-up data from one trial).

I hope objective outcome data can be included in a future revision or edition of this review.

Examples of objective outcomes include: exercise testing (work capacity by oxygen consumption); fitness test/step test; the six minute walking test; employment status; and disability payments.

Adding in these results would allow a more rigorous assessment of the effectiveness and relevance of the therapies, their causal mechanisms, therapeutic compliance, and safety.

On exercise testing, for example, in the PACE Trial (the largest trial in the review) there was no improvement in fitness levels as measured by a step test (2). The fitness data contrasts sharply with the many positive results from subjective self-report measures in the trial, so one is left wondering how much the subjective measures reflect reality.

On another exercise test used in the PACE Trial, the 6 minute walk test, there was a small (mean) increase from 312 metres at baseline to 379 metres at 12 months: this was 35.3 metres more than the "passive" control group when adjustments were made. However, the final result of 379 metres remains very poor compared to the more than 600 metres one would expect from healthy people of a similar age and gender make-up (3,4). By comparison, a group with Class III heart failure walked an average of 402 metres (5). A score of less than 400 metres has been suggested as the level at which somebody should be put on a lung transplant list (6). Such information from objective measures helps to add important context to the subjective measures and restraint to the conclusions that can be drawn from them.

Objective data is also needed to check compliance with a therapy. If patients diligently exercised for 12 months one would expect much better results on fitness and exercise testing than the aforementioned results in the PACE Trial. This is important when considering adverse events and safety: such trials may not give us good information on the safety of complying with such interventions if patients haven't actually complied.

Employment and receipt of disability payments are practical objective measures of general functional capacity so data on them would help establish whether patients can actually do more overall or whether they may just be doing, for example, a little more exercise but have substituted that for doing less in other areas (7,8). Also, CFS patients are sometimes pressured by insurance companies into doing graded exercise therapy (GET) programs so it would be useful to have data collated on employment outcomes to see whether pressure can in any way be justified (9,10). In the PACE Trial, there was no significant improvement in employment measures and receipt of disability payments in the GET group (11). Outside the realm of clinical trials, the quantitative and qualitative data in a major (UK) ME Association survey also found that GET didn't lead to higher levels of employment and lower levels of receipt of disability payments on average (9). Also, extensive external audits were performed of Belgian CFS rehabilitation clinics that treated using cognitive behavioural therapy (CBT) and GET. The main reports are in French and Dutch (12,13), with an English summary available (14) that says, "Employment status decreased at the end of the therapy, from an average of 18.3% of a 38h working week, to 14.9% [...] The percentage of patients living from a sickness allowance increased slightly from 54 to 57%." This contrasts with the average improvements reported in the audit for some symptoms like fatigue.

While data on (self-reported) symptoms like fatigue (one of your two primary outcomes) is interesting, arguably more important to patients is improving their overall level of functioning (and again, objective measures are needed here). Being able to work, for example, despite experiencing a certain level of fatigue would likely be more important for many than being unable to work but having slightly lower levels of fatigue.

An example of how reductions in the reported levels of fatigue may not lead to improvements in functioning can be seen in an analysis of three graded activity-oriented CBT therapy interventions for CFS (15). The analysis showed, compared to controls, there were no improvements in overall activity levels as measured by actometers despite improvements in self-reported fatigue (15). Activity in these trials was assessed using actometers. Another study that exemplifies the problem of focusing too much on fatigue scores after behavioural interventions is a study of CBT in multiple sclerosis (MS) patients with “MS fatigue”(16). The study found that following the intervention, patients with MS reported significantly lower (i.e. better) scores on the Chalder Fatigue Scale (0-33 scoring) than those in a healthy, nonfatigued comparison group! This significant difference was maintained at 3 and 6 months’ follow-up. It is difficult to believe that patients with MS fatigue (at baseline) truly subsequently had less fatigue than healthy nonfatigued controls: a much more likely scenario is that undertaking the intervention had led to response biases.

You mention that "many patient charities are opposed to exercise therapy for chronic fatigue syndrome (CFS)". One reason for concern about the way in which exercise programmes are promoted to patients is that they are often based upon models which assume that there is no abnormal physiological response to exercise in the condition, and make unsupported claims to patients. For example, in the FINE trial (Wearden et al., 2010) patient booklet (17), it is boldly asserted that: "Activity or exercise cannot harm you" (p. 49). However, a large number of studies have found abnormal responses to exercise, and the possibility of harm being done simply cannot be excluded on the basis of current evidence (discussed in 4, 18-20)."

Compliance

The review doesn't include any information on compliance. I'm not sure that there is much published information on this but I know there was a measure based on attendance at therapy sessions (which could be conducted over the phone) given for the PACE Trial (3). Ideally, it would be interesting if you could obtain some unpublished data from activity logs, records from heart-rate monitors, and other records to help build up a picture of what exercise was actually performed and the level of compliance. Information on adherence and what exercise was actually done is important in terms of helping clinicians, and indeed patients, to interpret and use the data. I mention patients because patients' own decisions about their behaviour is likely to be affected by the medical information available to them, both within and outside of a supervised programme of graded exercise; unlike with an intervention like a drug, patients can undertake exercise without professional supervision.

"Selective reporting (outcome bias)" and White et al. (2011)

I don't believe that White et al. (2011) (the PACE Trial) (3) should be classed as having a low risk of bias under "Selective reporting (outcome bias)" (Figure 2, page 15). According to the Cochrane Collaboration's tool for assessing risk of bias (21), the category of low risk of bias is for: "The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way". This is not the case in the PACE Trial. The three primary efficacy outcomes can be seen in the published protocol (22). None have been reported in the pre-specified way. The Cochrane Collaboration's tool for assessing risk of bias states that a “high risk” of bias applies if any one of several criteria are met, including that “not all of the study’s pre-specified primary outcomes have been reported” or “one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified”. In the PACE Trial, the third primary outcome measure (the number of "overall improvers") was never published. Also, the other two primary outcome measures were reported using analysis methods that were not pre-specified (including switching from the bimodal to the Likert scoring method for The Chalder Fatigue Scale, one of the primary outcomes in your review). These facts mean that the “high risk of bias” category should apply.

Thank you for taking the time to read my comments.

Tom Kindlon

Conflict of Interest statement:
I am a committee member of the Irish ME/CFS Association and do a variety of unpaid work for the Association.

References:

1. Turner L, Boutron I, Hróbjartsson A, Altman DG, Moher D: The evolution of assessing bias in Cochrane systematic reviews of interventions: celebrating methodological contributions of the Cochrane Collaboration. Syst Rev 2013, 2:79.

2. Chalder T, Goldsmith KA, White PD, Sharpe M, Pickles AR. Rehabilitative therapies for chronic fatigue syndrome: a secondary mediation analysis of the PACE trial. Lancet Psychiatry. 2015;2:141-152.

3. White PD, Goldsmith KA, Johnson AL, Potts L, Walwyn R, DeCesare JC, et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. The Lancet 2011;377:823-36.

4. Kindlon T. Reporting of Harms Associated with Graded Exercise Therapy and Cognitive Behavioural Therapy in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Bull IACFS ME. 2011;19:59-111. http://iacfsme.org/ME-CFS-Primer-Education/Bulletins/BulletinRelatedPages5/Reporting-of-Harms-Associated-with-Graded-Exercise.aspx

5. Lipkin DP, Scriven AJ, Crake T, Poole-Wilson PA (1986). Six minute walking test for assessing exercise capacity in chronic heart failure. British Medical Journal 292, 653-5.

6. Kadikar A, Maurer J, Kesten S. The six-minute walk test: a guide to assessment for lung transplantation. J Heart Lung Transplant. 1997 Mar;16(3):313-9.

7. Friedberg F, Sohl S. Cognitive-behavior therapy in chronic fatigue syndrome: is improvement related to increased physical activity? J Clin Psychol. 2009 Feb 11.

8. Friedberg F. Does graded activity increase activity? A case study of chronic fatigue syndrome. Journal of Behavior Therapy and Experimental Psychiatry, 2002, 33, 3-4, 203-215

9. Results and In-depth Analysis of the 2012 ME Association Patient Survey Examining the Acceptability, Efficacy and Safety of Cognitive Behavioural Therapy, Graded Exercise Therapy and Pacing, as Interventions used as Management Strategies for ME/CFS. Gawcott, England. http://www.meassociation.org.uk/2015/05/23959/ Accessed: September 3, 2015

10. Critical Illness - A Dreadful Experience with Scottish Provident. http://forums.moneysavingexpert.com/showthread.php?t=2356683 Accessed: September 4, 2015

11. McCrone P, Sharpe M, Chalder T, Knapp M, Johnson AL, Goldsmith KA, White PD. Adaptive pacing, cognitive behaviour therapy, graded exercise, and specialist medical care for chronic fatigue syndrome: a cost-effectiveness analysis. PLoS One. 2012;7(8):e40808.

12. Rapport d’évaluation (2002-2004) portant sur l’exécution des conventions de rééducation entre le Comité de l’assurance soins de santé (INAMI) et les Centres de référence pour le Syndrome de fatigue chronique (SFC). 2006. http://health.belgium.be/internet2Prd/groups/public/@public/@shc/documents/ie2divers/14926531_fr.pdf (Starts on page 223.) Accessed September 4, 2015 (French language edition)

13. Evaluatierapport (2002-2004) met betrekking tot de uitvoering van de revalidatieovereenkomsten tussen het Comité van de verzekering voor geneeskundige verzorging (ingesteld bij het Rijksinstituut voor Ziekte- en invaliditeitsverzekering) en de Referentiecentra voor het Chronisch vermoeidheidssyndroom (CVS). 2006. http://health.belgium.be/internet2Prd/groups/public/@public/@shc/documents/ie2divers/14926531.pdf (Starts on page 227.) Accessed September 4, 2015 (Dutch language version)

14. Stordeur S, Thiry N, Eyssen M. Chronisch Vermoeidheidssyndroom: diagnose, behandeling en zorgorganisatie. Health Services Research (HSR). Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE); 2008. KCE reports 88A (D/2008/10.273/58) https://kce.fgov.be/sites/default/files/page_documents/d20081027358.pdf Accessed September 4, 2015

15. Wiborg JF, Knoop H, Stulemeijer M, Prins JB, Bleijenberg G. How does cognitive behaviour therapy reduce fatigue in patients with chronic fatigue syndrome? The role of physical activity. Psychol Med. 2010; 40:1281-1287.

16. Van Kessel K, Moss-Morris R, Willoughby, Chalder T, Johnson MH, Robinson E, A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue, Psychosom. Med. 2008; 70:205–213.

17. Powell P. FINE Trial Patient Booklet http://www.fine-trial.net/downloads/Patient%20PR%20Manual%20ver9%20Apr05.pdf Accessed September 7, 2015

18. Twisk FNM, Maes M. A review on Cognitive Behavorial Therapy (CBT) and Graded Exercise Therapy (GET) in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS. Neuro Endocrinol Lett. 2009;30:284-299.

19. Carruthers BM et al. Myalgic Encephalomyelitis – Adult & Paediatric: International Consensus Primer for Medical Practitioners. ISBN 978-0-9739335-3-6 http://www.investinme.org/Documents/Guidelines/Myalgic%20Encephalomyelitis%20International%20Consensus%20Primer%20-2012-11-26.pdf Accessed September 5, 2015

20. Twisk FN. Objective Evidence of Post-exertional “Malaise” in Myalgic Encephalomyelitis and Chronic Fatigue Syndrome. J Sports Med Doping Stud 2015. 5:159. doi: 10.4172/2161-0673.1000159

21. Higgins JPT, Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Table 8.5.d. The Cochrane Collaboration; 2011. http://handbook.cochrane.org/chapte...a_for_judging_risk_of_bias_in_the_risk_of.htm Accessed: September 5, 2015

22. White PD, Sharpe MC, Chalder T, DeCesare JC, Walwyn R; on behalf of the PACE trial group. Protocol for the PACE trial: A randomised controlled trial of adaptive pacing, cognitive behaviour therapy, and graded exercise as supplements to standardised specialist medical care versus standardised specialist medical care alone for patients with the chronic fatigue syndrome/myalgic encephalomyelitis or encephalopathy. BMC Neurology 2007, 7:6 http://www.biomedcentral.com/1471-2377/7/6 Accessed: September 5, 2015
 
Last edited:

Tom Kindlon

Senior Member
Messages
1,734
Comment on: Exercise therapy for chronic fatigue syndrome. Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Cochrane Database Syst Rev. 2015 Feb 10;2:CD003200.

Author: Tom Kindlon

Comment 2 of 2 submitted on September 9, 2015

Second comment:

I have decided to split my comment into two as it was getting very long. This is part two.

Variation in interventions

It would have been useful to have some more information on the “exercise with pacing” intervention tested in the Wallman et al. (2004) trial and how it was distinct from some other exercise interventions tested. The authors say (1): “On days when symptoms are worse, patients should either shorten the session to a time they consider manageable or, if feeling particularly unwell, abandon the session altogether” (p. 143). I don't believe the description given in the review conveys this. In the review, this approach is described as "Exercise with pacing: exercise in which the incremental increase in exercise was personally set." But Wallman et al.’s approach allows patients to decrease as well as increase how much exercise they do on the day. This approach also contrasts with how White (an investigator in two of the trials) has described graded exercise therapy: "if [after increasing the intensity or duration of exercise] there has been an increase in symptoms, or any other adverse effects, they should stay at their current level of exercise for a further week or two, until the symptoms are back to their previous levels" (2). In the PACE Trial manual White co-wrote (3), the GET intervention was guided by the principle that “planned physical activity and not symptoms are used to determine what the participant does” (p. 21); similarly, “it is their planned physical activity, and not their symptoms, that determine what they are asked to do” (p. 20). Compliance data would help us examine which approach patients are actually using: I suspect many patients are in fact doing exercise with pacing even in trials such as the PACE Trial (i.e. when they have increased symptoms, often reducing levels of exercise and sometimes doing no exercise activities at all on that day).

Bimodal versus Likert scoring in Wearden et al. (2010)

I find it odd that the fatigue scores for the Wearden et al. (2010) trial (4) are given in the 0-33 format rather than the 0-11 scoring method. The 0-11 scoring system is what is mentioned as a primary outcome measure in the protocol and is what is reported in the main paper reporting the results (4, 5). It is even what your own report says on p. 44 is the scoring method (“Fatigue Scale, FS; 11 items; each item was scored dichotomously on a 4-point scale [0, 0, 1 or 1]”). This is important because using the scoring method for which you don't report data (0-11), there is no statistically significant difference at the primary outcome point of 70 weeks (5).

Diagnostic criteria

One problem with using these trials as an evidence base, which I don't believe was mentioned, is that all the trials used the Oxford and Fukuda diagnostic criteria (6, 7). Neither of these criteria require patients to have post-exertional malaise (or something similar). Many consider this to be a core symptom of ME/CFS and it is mandatory in most of the other major criteria (8-11). [Aside: The London criteria were assessed in the PACE Trial (12) but they seem to have been operationalised in an unusual way. Ninety seven per cent of the participants who satisfied the (broad) Oxford criteria who didn't have a psychiatric disorder satisfied the definition of M.E. used (13). Ellen Goudsmit, one of the authors of the London criteria, has rejected the way they were used in the PACE Trial (14)]. So this lack of requirement for patients to have post-exertional malaise (or a similar description) means we cannot be sure that the evidence can be generalised to such patients. An independent National Institutes of Health committee this year concluded "continuing to use the Oxford definition may impair progress and cause harm. Therefore, for progress to occur, we recommend that this definition be retired" (15). An Agency for Healthcare Research and Quality review of diagnostic methods this year reached a similar conclusion: "Consensus groups and researchers should consider retiring the Oxford case definition because it differs from the other case definitions and is the least restrictive, probably including individuals with other overlapping conditions” (16). An Agency for Healthcare Research and Quality review of ME/CFS treatments said: "The Oxford CFS case definition is the least restrictive, and its use as entry criteria could have resulted in selection of participants with other fatiguing illnesses or illnesses that resolve spontaneously with time" (17).

Exclusion of some data from analyses due to baseline differences

It seems unfortunate that some data cannot be used due to baseline differences e.g. "Four trials (669 participants) contributed data for evaluation of physical functioning at follow-up (Jason 2007; Powell 2001; Wearden 2010; White 2011). Jason 2007 observed better results among participants in the relaxation group (MD 21.48, 95% CI 5.81 to 37.15). However, results were distorted by large baseline differences in physical functioning between the exercise and relaxation groups (39/100 vs 54/100); therefore we decided not to include these results in the meta-analysis". It would be good if other methods could be investigated (e.g. using baseline levels as covariates) to analyse such data.

Thank you for taking the time to read my comments.

Tom Kindlon

Conflict of Interest statement:
I am a committee member of the Irish ME/CFS Association and do a variety of unpaid work for the Association.

References

1. Wallman KE, Morton AR, Goodman C, Grove R. Exercise prescription for individuals with chronic fatigue syndrome. Med J Aust. 2005;183:142-3.

2. White P. How exercise can help chronic fatigue syndrome. Pulse: 1998. June 20:86-87.

3. Bavinton J, Darbishire L, White PD -on behalf of the PACE trial management group. Graded Exercise Therapy for CFS/ME (Therapist Manual) http://www.pacetrial.org/docs/get-therapist-manual.pdf

4. Wearden AJ, Riste L, Dowrick C, Chew-Graham C, Bentall RP, Morriss RK, Peters S, Dunn G, Richardson G, Lovell K, Powell P. Fatigue Intervention by Nurses Evaluation--the FINE Trial. A randomised controlled trial of nurse led self-help treatment for patients in primary care with chronic fatigue syndrome: study protocol. [ISRCTN74156610]. BMC Med. 2006 Apr 7;4:9.

5. Wearden AJ, Dowrick C, Chew-Graham C, Bentall RP, Morriss RK, Peters S, Riste L, Richardson G, Lovell K, Dunn G; Fatigue Intervention by Nurses Evaluation (FINE) trial writing group and the FINE trial group. Nurse led, home based self help treatment for patients in primary care with chronic fatigue syndrome: randomised controlled trial. BMJ. 2010 Apr 23;340:c1777. doi: 10.1136/bmj.c1777.

6. Sharpe M, Archard L, Banatvala J, Borysiewicz LK, Clare AW, David A, et al. Chronic fatigue syndrome: guidelines for research. Journal of the Royal Society of Medicine 1991;84 (2):118–21.

7. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: A comprehensive approach to its definition and study. Ann Intern Med. 1994; 121: 953‑959.

8. Carruthers BM, Jain AK, De Meirleir KL, et al. Myalgic Encephalomyelitis/chronic fatigue syndrome: Clinical working case definition, diagnostic and treatments protocols. Journal of Chronic Fatigue Syndrome. 2003; 11: 7-115.

9. Carruthers BM, van de Sande MI, De Meirleir KL, et al. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med. 2011; 270: 327-338.

10. IOM (Institute of Medicine). Beyond myalgic encephalomyelitis/chronic fatigue syndrome: Redefining an illness. Washington, DC: The National Academies; 2015.

11. National Institute for Health and Clinical Excellence. Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management of CFS/ME in adults and children, 2007. http://www.nice.org.uk/guidance/CG53 Accessed September 6, 2015. London: National Institute for Health and Clinical Excellence.

12. White PD, Goldsmith KA, Johnson AL, Potts L, Walwyn R, DeCesare JC, et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. The Lancet 2011;377:823-36.

13. Kindlon T. PACE Trial - 97% of the participants who didn't have a psychiatric disorder satisfied the definition of M.E. used. https://listserv.nodak.edu/cgi-bin/wa.exe?A2=ind1106A&L=CO-CURE&P=R2764 Accessed: September 6, 2015

14. Ellen Goudsmit on PubMed Commons: http://www.ncbi.nlm.nih.gov/myncbi/ellen m.goudsmit.1/comments/

15. Green CR, Cowan P, Elk R, O'Neil KM, Rasmussen AL. National Institutes of Health Pathways to Prevention Workshop: advancing the research on myalgic encephalomyelitis/chronic fatigue syndrome. Ann Intern Med. 2015; 162:860-5.

16. Haney E, Smith MEB, McDonagh M, Pappas M, Daeges M, Wasson N, et al. Diagnostic methods for myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015; 162:834-40.

17. Smith MEB, Haney E, McDonagh M, Pappas M, Daeges M, Wasson N, et al. Treatment of myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015; 162:841-50.
 
Last edited:

Tom Kindlon

Senior Member
Messages
1,734

Tom Kindlon

Senior Member
Messages
1,734
@Bob posted this elsewhere: http://forums.phoenixrising.me/inde...cochrane-report-says.35474/page-6#post-637835

Note that there's also a complaints procedure at Cochrane, but I think it would be appropriate to raise issues in relation to the content of a review via a comment submission first, and only take it to complaint if it isn't resolved satisfactorily.

Details on submitting a comment and what happens to comments:
http://www.cochranelibrary.com/help/submitting-comments-on-cochrane-reviews.html

Details on the complaints procedure:
http://community.cochrane.org/edito...esource/cochrane-library-complaints-procedure

If anyone is thinking of submitting anything, it might be useful if you could let me know in this thread or via private message, so we don't double up.
 

Tom Kindlon

Senior Member
Messages
1,734
They included two earlier comments in the current pdf so think/hope it can be useful to submit comments

Your comment has been submitted

Thank you for submitting your comments on 'Exercise therapy for chronic fatigue syndrome'.

The Cochrane Collaboration welcomes feedback on Cochrane Reviews as it helps to improve the quality of reviews.

What happens next?
Your comment will be read by an editor at Wiley within the next two working days. If your comments abide by ‘The Cochrane Library Terms of Use’, it will be passed to the Cochrane Review Group http://www.cochrane.org/contact/review-groups responsible for the review.

The Review Group’s editorial team will review your comments and will contact you to acknowledge receipt and to let you know their response. The Group may publish your comments as part of the review. The Group may also seek a response from the review authors, which may also be published. The review may be amended to reflect your comments, or your comments may have an impact on the next update of the review.
If you have any concerns about the progress or handling of your comment, please visit the Help menu of The Cochrane Library website http://www.thecochranelibrary.com/view/0/CochraneLibraryComplaintsProcedure.html
 

Tom Kindlon

Senior Member
Messages
1,734
After you submit things, you'll often then be reminded of things you could have said.

This is a published piece that would have fit in with what I was saying:

http://onlinelibrary.wiley.com/doi/10.1111/cpsp.12042/abstract

Commentary

Does Cognitive Behavioral Therapy or Graded Exercise Therapy Reduce Disability in Chronic Fatigue Syndrome Patients? Objective Measures Are Necessary

Andrew James Kewley*

Article first published online: 16 SEP 2013

DOI: 10.1111/cpsp.12042

Issue

Clinical Psychology: Science and Practice

Volume 20, Issue 3, pages 321–322, September 2013

Keywords:

actigraphy;
actometer;
chronic fatigue syndrome;
cognitive behavioral therapy;
disability;
graded exercise therapy;
myalgic encephalomyelitis;
neuropsychological testing

Clinical trials of cognitive behavioral therapy and graded exercise therapy have consistently demonstrated improvement in self-reported quality of life and improvement of symptoms. However, due to the nature of these therapies, it is not possible to carry out a double-blinded trial design or fully control for reporting biases. Therefore, to make strong claims about efficacy and reductions in disability, objective methods should be used such as neuropsychological testing, actigraphy, and repeat exercise testing.
 

Tom Kindlon

Senior Member
Messages
1,734
Another thing I've referenced before but forgot to reference here was a Whiting et al. (2001) review:

The review recommended the use of more objective outcome measures e.g.
"Outcomes such as "improvement," in which participants were asked to rate themselves as better or worse than they were before the intervention began, were frequently reported. However, the person may feel better able to cope with daily activities because they have reduced their expectations of what they should achieve, rather than because they have made any recovery as a result of the intervention. A more objective measure of the effect of any intervention would be whether participants have increased their working hours, returned to work or school, or increased their physical activities."

Whiting P, Bagnall AM, Sowden AJ, Cornell JE, Mulrow CD, Ramírez G. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. JAMA. 2001 Sep 19;286(11):1360-8.